SEGMENT INFORMATION (Tables)

6 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

SCHEDULE OF FINANCIAL INFORMATION OF REPORTABLE SEGMENT

Summarized financial information concerning the Company’s reportable segments is shown as below:

By Categories

	For the three months ended June 30, 2022
	Therapeutic Operations			ESG Operations			Corporate			Total
Revenue	$	-		$	639,359		$	-		$	639,359
Cost of services		-			574,407			-			574,407
Gross profit		-			64,952			-			64,952
Net loss		(107,823	)	$	(39,429	)	$	(295,934	)	$	(443,186	)
Total assets		8,334			3,855,184			1,661,781			5,525,299
Capital expenditures for long-lived assets	$	-		$	1,107,833		$	-		$	1,107,833

	For the six months ended June 30, 2022
	Therapeutic Operations			ESG Operations			Corporate			Total
Revenue	$	-		$	639,359		$	-		$	639,359
Cost of services		-			574,407			-			574,407
Gross profit		-			64,952			-			64,952
Net loss		(233,553	)	$	(60,146	)	$	(597,461	)	$	(891,160	)
Total assets		8,334			3,855,184			1,661,781			5,525,299
Capital expenditures for long-lived assets	$	-		$	1,107,833		$	-		$	1,107,833

	For the three months ended June 30, 2021
	Therapeutic Operations			ESG Operations		Corporate			Total
Net loss	$	(97,812	)	$	-	$	(514,423	)	$	(612,235	)
Total assets		-			-		331,138			331,138
Capital expenditures for long-lived assets	$	-		$	-	$	-		$	-

	For the six months ended June 30, 2021
	Therapeutic Operations			ESG Operations		Corporate			Total
Net loss	$	(168,449	)	$	-	$	(804,417	)	$	(972,866	)
Total assets		-			-		331,138			331,138
Capital expenditures for long-lived assets	$	-		$	-	$	-		$	-